Lista de obras - Paolo Nuciforo - Dominio Público Uruguay

155PDTumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial

2399 Impact of KRAS mutations on clinical outcomes in advanced refractory pancreatic cancer patients

303: A role for senescent cell-derived IL6 in HER2+ breast cancer progression

426TiPFirst-in-human study of AMC303 as monotherapy in patients with advanced solid tumor of epithelial origin

430ODifferent RNA expression profile defines prognosis in grade 1/2 neuroendocrine neoplasms of small intestine origin: The GETNE-NETSEQ study

432PDPrognostic impact of RNA expression profile (EP) in the phase III DECISION trial for patients with advanced radioactive-iodine refractory differentiated thyroid cancer (DTC)

8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes

artículo científico publicado en 2005

A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade

artículo científico publicado en 2017

A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status

artículo científico publicado en 2011

Abstract 2088: The activity of the FGFR selective inhibitor Debio 1347 is correlated with high mRNA expression

Abstract 4784: FGFR-selective inhibitor Debio 1347 induces tumor regressions in FGFR2-altered gastric cancer PDX models

Abstract B02: Co-clinical trial of olaparib in breast and ovarian patient-derived tumor xenografts (PDX) enables the identification of response biomarkers

Abstract GS1-04: Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial

Abstract P2-05-04: Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial

Abstract P2-09-01: T-cell receptor beta chain variable region (TRBV) expression patterns predict response to combined trastuzumab/lapatinib treatment in the NeoALTTO/BIG-1-06 trial

Abstract P2-09-14: A predictive model of pathological response following dual HER2 blockade-only based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer

Abstract P3-10-24: Fibroblast Growth Factor Receptor 1 Amplification and Overexpression in Breast Cancer Tissue Microarrays Using Chromogenic In Situ Hybridization and Immunohistochemistry

Abstract P5-20-19: PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13-03) trial

Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage brea

Abstract S3-03: PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial

Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer

artículo científico publicado en 2021

Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor

artículo científico publicado en 2009

An atlas of altered expression of deubiquitinating enzymes in human cancer

artículo científico publicado en 2011

Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer.

artículo científico publicado en 2017

Analysis of mismatch repair (MMR) genes and pd-l1 expression in invasive micropapillary carcinoma of the breast (IMPCS)

article

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Ca

artículo científico publicado en 2017

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in I

artículo científico publicado en 2017

Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial

Breast cancer metastases are molecularly distinct from their primary tumors

artículo científico publicado en 2007

Brn-2 Represses Microphthalmia-Associated Transcription Factor Expression and Marks a Distinct Subpopulation of Microphthalmia-Associated Transcription Factor-Negative Melanoma Cells

artículo científico publicado en 2008

CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours

artículo científico publicado en 2003

CORRESPONDENCE RE: BONETTI F, MARTIGNONI G, COLATO C, MANFRIN E, GAMBACORTA M, FALERI M, ET AL. ABDOMINOPELVIC SARCOMA OF PERIVASCULAR EPITHELIOID CELLS. REPORT OF FOUR CASES IN YOUNG WOMEN, ONE WITH TUBEROUS SCLEROSIS. MOD PATHOL 2001;14:563–8. AN

artículo científico publicado en 2002

Cancer stem cell theory: pathologists' considerations and ruminations about wasting time and wrong evaluations.

artículo científico publicado en 2004

Cancer stem cells: the neoplastic disease from a different view point

artículo científico publicado en 2005

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

artículo científico

Chromosomal rearrangements in acute myeloid leukemia (AML).

artículo científico publicado en 2010

Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall d’Hebron Institute of Oncology phase I program cohort

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.

artículo científico publicado en 2013

Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype

scientific article published on 01 August 2020

Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression

artículo científico publicado en 2007

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer

artículo científico publicado en 2017

Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti-Salmonella typhimurium immunity

artículo científico publicado en 2008

Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti–Salmonella typhimuriumimmunity

Corrigendum: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

artículo científico publicado en 2018

DNA damage repair and telomere length in normal breast, preneoplastic lesions, and invasive cancer

artículo científico publicado en 2010

ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity

artículo científico publicado en 2015

Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy

artículo científico publicado en 2020

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

artículo científico publicado en 2014

Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing

artículo científico publicado en 2013

Estrogen receptor and human epidermal growth factor receptor-2 quantification and efficacy to trastuzumab

Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies

artículo científico publicado en 2013

Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy

scientific article published on 25 October 2019

First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours

artículo científico publicado en 2017

Frequent alterations in the expression of serine/threonine kinases in human cancers

artículo científico publicado en 2006

Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

scientific article published on 22 July 2016

Gene expression analysis of early and advanced gastric cancers.

artículo científico publicado en 2007

Genetic alterations in the PI3K/AKT pathway and baseline AKT activity define AKT inhibitor sensitivity in breast cancer patient-derived xenografts

scientific article published on 27 March 2020

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

artículo científico publicado en 2014

Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity

artículo científico publicado en 2013

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.

artículo científico publicado en 2014

High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.

artículo científico publicado en 2015

Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial

artículo científico publicado en 2019

Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment

scientific article published on 08 March 2021

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.

artículo científico publicado en 2017

Immunohistochemistry protocol for γH2AX detection (formalin-fixed paraffin-embedded sections)

Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.

artículo científico publicado en 2017

LBA10_PRPrimary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)

LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy

scientific article published on 11 June 2019

LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells

scientific article published on 28 August 2019

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.

artículo científico publicado en 2018

Lymphomas of the Bone: A Pathological and Clinical Study of 54 Cases

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.

scientific article published on 13 August 2015

Malakoplakia of the pancreas with diffuse lymph-node involvement

artículo científico publicado en 2002

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients

artículo científico publicado en 2015

Mitf regulation of Dia1 controls melanoma proliferation and invasiveness

artículo científico publicado en 2006

Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma

artículo científico publicado en 2003

Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors

artículo científico

NUMB controls p53 tumour suppressor activity

artículo científico publicado en 2008

O-024Circulating tumor DNA extended RAS mutational analysis as a surrogate of mutational status of tumor samples in metastatic colorectal cancer and its impact on patient selection for anti-EGFR therapy

Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic

scientific article published on 04 September 2014

Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication

artículo científico publicado en 2006

PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analy

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

artículo científico publicado en 2015

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

artículo científico publicado en 2015

Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial

scientific article published on 16 September 2020

Pathologic quiz case: a scrotal sac mass incidentally discovered during autopsy

artículo científico publicado en 2003

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial

artículo científico publicado en 2017

Patient-derived AVATAR mouse models to predict prognosis in advanced renal cell carcinoma

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies

artículo científico publicado en 2015

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

scientific article published on 20 January 2020

Pirin inhibits cellular senescence in melanocytic cells.

artículo científico publicado en 2011

Preclinical activity of PI3K inhibitor Copanlisib in Gastrointestinal Stromal Tumor

scientific article published on 05 May 2020

Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay

artículo científico publicado en 2015

Prep1 (pKnox1)-deficiency leads to spontaneous tumor development in mice and accelerates EmuMyc lymphomagenesis: a tumor suppressor role for Prep1.

artículo científico publicado en 2010

Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.

artículo científico publicado en 2016

Prognostic impact of KRAS mutation in metastatic (met) pancreatic cancer patients (pts)

Quantification of HER family receptors in breast cancer

artículo científico publicado en 2015

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer.

artículo científico publicado en 2018

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

artículo científico

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

artículo científico publicado en 2022

Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes

scientific journal article

Survival prediction of stage I lung adenocarcinomas by expression of 10 genes

artículo científico publicado en 2007

TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence

artículo científico publicado en 2018

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.

artículo científico publicado en 2015

Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer

artículo científico publicado en 2019

Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions

artículo científico publicado en 2008

The Fragile X Protein binds mRNAs involved in cancer progression and modulates metastasis formation

artículo científico publicado en 2014

The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium

artículo científico publicado en 2008

The fragile X protein binds mRNAs involved in cancer progression and modulates metastasis formation

artículo científico publicado en 2013

The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer

artículo científico publicado en 2009

Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response

artículo científico publicado en 2007

Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy

artículo científico publicado en 2018

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial

artículo científico

Tumor-infiltrating lymphocytes density correlates with HER2 gene copy number but not with protein levels in HER2-positive breast cancer

article

Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system

artículo científico publicado en 2012

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.

artículo científico publicado en 2017

p95HER2-T cell bispecific antibody for breast cancer treatment

artículo científico publicado en 2018

Lista de obras de Paolo Nuciforo

155PDTumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial

2399 Impact of KRAS mutations on clinical outcomes in advanced refractory pancreatic cancer patients

303: A role for senescent cell-derived IL6 in HER2+ breast cancer progression

426TiPFirst-in-human study of AMC303 as monotherapy in patients with advanced solid tumor of epithelial origin

430ODifferent RNA expression profile defines prognosis in grade 1/2 neuroendocrine neoplasms of small intestine origin: The GETNE-NETSEQ study

432PDPrognostic impact of RNA expression profile (EP) in the phase III DECISION trial for patients with advanced radioactive-iodine refractory differentiated thyroid cancer (DTC)

8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes

A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade

A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status

Abstract 2088: The activity of the FGFR selective inhibitor Debio 1347 is correlated with high mRNA expression

Abstract 4784: FGFR-selective inhibitor Debio 1347 induces tumor regressions in FGFR2-altered gastric cancer PDX models

Abstract B02: Co-clinical trial of olaparib in breast and ovarian patient-derived tumor xenografts (PDX) enables the identification of response biomarkers

Abstract GS1-04: Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial

Abstract P2-05-04: Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial

Abstract P2-09-01: T-cell receptor beta chain variable region (TRBV) expression patterns predict response to combined trastuzumab/lapatinib treatment in the NeoALTTO/BIG-1-06 trial

Abstract P2-09-14: A predictive model of pathological response following dual HER2 blockade-only based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer

Abstract P3-10-24: Fibroblast Growth Factor Receptor 1 Amplification and Overexpression in Breast Cancer Tissue Microarrays Using Chromogenic In Situ Hybridization and Immunohistochemistry

Abstract P5-20-19: PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13-03) trial

Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage brea

Abstract S3-03: PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial

Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer

Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor

An atlas of altered expression of deubiquitinating enzymes in human cancer

Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer.

Analysis of mismatch repair (MMR) genes and pd-l1 expression in invasive micropapillary carcinoma of the breast (IMPCS)

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Ca

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in I

Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial

Breast cancer metastases are molecularly distinct from their primary tumors

Brn-2 Represses Microphthalmia-Associated Transcription Factor Expression and Marks a Distinct Subpopulation of Microphthalmia-Associated Transcription Factor-Negative Melanoma Cells

CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours

CORRESPONDENCE RE: BONETTI F, MARTIGNONI G, COLATO C, MANFRIN E, GAMBACORTA M, FALERI M, ET AL. ABDOMINOPELVIC SARCOMA OF PERIVASCULAR EPITHELIOID CELLS. REPORT OF FOUR CASES IN YOUNG WOMEN, ONE WITH TUBEROUS SCLEROSIS. MOD PATHOL 2001;14:563–8. AN

Cancer stem cell theory: pathologists' considerations and ruminations about wasting time and wrong evaluations.

Cancer stem cells: the neoplastic disease from a different view point

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

Chromosomal rearrangements in acute myeloid leukemia (AML).

Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall d’Hebron Institute of Oncology phase I program cohort

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.

Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype

Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer

Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti-Salmonella typhimurium immunity

Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti–Salmonella typhimuriumimmunity

Corrigendum: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

DNA damage repair and telomere length in normal breast, preneoplastic lesions, and invasive cancer

ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity

Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing

Estrogen receptor and human epidermal growth factor receptor-2 quantification and efficacy to trastuzumab

Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies

Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy

First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours

Frequent alterations in the expression of serine/threonine kinases in human cancers

Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

Gene expression analysis of early and advanced gastric cancers.

Genetic alterations in the PI3K/AKT pathway and baseline AKT activity define AKT inhibitor sensitivity in breast cancer patient-derived xenografts

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.

High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.

Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial

Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.

Immunohistochemistry protocol for γH2AX detection (formalin-fixed paraffin-embedded sections)

Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.

LBA10_PRPrimary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)

LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy

LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.

Lymphomas of the Bone: A Pathological and Clinical Study of 54 Cases

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.

Malakoplakia of the pancreas with diffuse lymph-node involvement

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients

Mitf regulation of Dia1 controls melanoma proliferation and invasiveness

Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma

Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors

NUMB controls p53 tumour suppressor activity

O-024Circulating tumor DNA extended RAS mutational analysis as a surrogate of mutational status of tumor samples in metastatic colorectal cancer and its impact on patient selection for anti-EGFR therapy